We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellomics and Evotec Sign License Agreement

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Cellomics and Evotec Sign License Agreement"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH have announced that they have entered into a worldwide, non-exclusive patent license agreement. 

The agreement will provide Evotec Technologies with Cellomics' core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization.

This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.

Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics' and Evotec Technologies' products as seamless solutions. 

"We are excited to extend the application portfolio of our Opera™ platform through this partnership with Cellomics," said Dr Guenter Bauer, chief business officer at Evotec Technologies GmbH.

"The combination of highest quality cell assays and highest quality automation will provide important and completely new insight into the biomolecular network of cells."

"Industrialized experimental strategies replace large singular efforts in the new field of systems biology and will ultimately lead to the development of new therapies for diseases."

The two companies will improve the compatibility and integration of their software and assay products, including validation of Cellomics' assay kits by Evotec Technologies. 

Additional efforts will bring two-way data flow between the complementary platforms and access to enterprise-wide data storage, management, and analysis.

Daniel J. Calvo, president of Cellomics, added, "We are very pleased to partner with Evotec Technologies to expand the use of Cellomics technologies across a broader range of applications and throughput protocols."

"The Opera instrument is very complementary with our ArrayScan® HCS Reader platform. This cooperative development will enable more productive adoption of HCS by our customers, from assay development to screening to ADME/Tox."